Medical News

RSS

TGAC plans to use miniaturised sequencing device to conduct live environmental surveillance

As one of the first research Institutes to take part in the MinION Access Programme (MAP) for portable DNA sequencing, introduced by Oxford Nanopore Technologies, The Genome Analysis Centre (TGAC)'s task force share their experience of the ground breaking trial so far.

From Oxford Nanopore Technologies 23 Mar 2015

Radiation treatment can be delayed after prostatectomy to prevent side effects, say studies

Important news for men receiving treatment for prostate cancer: Two new studies from the University of Virginia School of Medicine have upended the widely held view that it's best to delay radiation treatment as long as possible after the removal of the prostate in order to prevent unwanted side effects.

23 Mar 2015

Mast plans to develop vepoloxamer for chronic heart failure treatment

Mast Therapeutics, Inc., a clinical-stage biopharmaceutical company leveraging its molecular adhesion and sealant technology (MAST) platform to develop novel therapies for sickle cell disease, arterial disease and heart failure, today announced its plans to develop vepoloxamer (MST-188) for the treatment of patients with chronic heart failure.

23 Mar 2015

Glyxambi for Type 2 diabetes treatment now available by prescription across the U.S.

Glyxambi® (empagliflozin/linagliptin) tablets are now available by prescription in many leading chain and independent pharmacies across the U.S., including Walgreens and Rite Aid.

23 Mar 2015

Cipher to distribute Can-Fite’s CF101 for plaque psoriasis and rheumatoid arthritis treatment in Canada

Cipher Pharmaceuticals Inc. today announced it has licensed the Canadian distribution rights to CF101, a novel chemical entity being developed by Can-Fite Biopharma for moderate to severe plaque psoriasis and rheumatoid arthritis.

23 Mar 2015

Students at Penn State College of Medicine celebrate matching with residency programs

Today, 120 fourth-year medical students at Penn State College of Medicine learned where they will spend their residencies in an annual tradition known as Match Day. A similar scene played out with fourth-year students at medical schools across the country.

23 Mar 2015

NNI publishes report on nanotechnology environmental, health, and safety risk science status

The National Nanotechnology Initiative (NNI) today published the report from the workshop, "Stakeholder Perspectives on Perception, Assessment, and Management of the Potential Risks of Nanotechnology" (R3 Workshop), which was held September 10-11, 2013, in Washington, D.C.

23 Mar 2015

EHT expert paper raises important and unanswered questions about safety of wearable tech

Wearable technology is raising health concerns worldwide. A recent New York Times article by Nick Bilton is raising important and unanswered questions about the safety of wearable tech, according to the non-profit research group, Environmental Health Trust.

23 Mar 2015

Point-Person Project may be more successful with a national infrastructure for clinical trials

A study reported in this week's Science Translational Medicine found that qualified investigators are more likely to respond to opportunities for clinical trials if they are contacted by an institution-specific point person, or navigator.

23 Mar 2015

MEI Pharma reports top-line results from Pracinostat Phase II study in patients with high-risk MDS

MEI Pharma, Inc., an oncology company focused on the clinical development of novel therapies for cancer, today announced top-line data from a randomized Phase II clinical study of its investigational drug candidate Pracinostat in combination with azacitidine in patients with previously untreated intermediate-2 or high-risk myelodysplastic syndrome (MDS).

23 Mar 2015

OrthoSensor raises $19 million in Series C Preferred Stock financing

OrthoSensor, Inc., the leader in Sensor-Assisted Surgery, announced today that it has raised $19 million in a private placement of Series C Preferred Stock. Bridger Healthcare, Ltd. and The Tullis Growth Fund, L.P. participated in the round. The proceeds will be used to drive the commercialization of VERASENSE, OrthoSensor's leading product, and expand product development activities.

23 Mar 2015

Isis Pharmaceuticals announces positive results from ISIS-ANGPTL3Rx Phase 1 study

Isis Pharmaceuticals, Inc. announced today positive results from a Phase 1 study with ISIS-ANGPTL3Rx. In this study, healthy volunteers treated with ISIS-ANGPTL3Rx achieved dose-dependent, statistically significant reductions in angiopoietin-like 3 (ANGPTL3) of up to 93 percent with a mean reduction of up to 84 percent from baseline (p<0.001).

23 Mar 2015

Study: Medical practices need support and guidance to adopt new payment models

Physician practices are engaging in new health care payment models intended to improve quality and reduce costs, but are finding that they need help with successfully managing increasing amounts of data and figuring out how to respond to the diversity of programs and quality metrics from different payers, according to a new joint study by the RAND Corporation and the American Medical Association.

23 Mar 2015

Everyday Health announces acquisition of Cambridge BioMarketing Group

Everyday Health, Inc., a leading provider of digital health and wellness solutions, today acquired Cambridge BioMarketing Group, LLC, the leader in strategic launch and marketing solutions for orphan and rare disease products.

23 Mar 2015

Low-calorie rice could help potentially reduce obesity rates

Scientists have developed a new, simple way to cook rice that could cut the number of calories absorbed by the body by more than half, potentially reducing obesity rates, which is especially important in countries where the food is a staple.

23 Mar 2015

Can-Fite, Cipher Pharmaceuticals sign agreement to distribute CF101 in Canada

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that are being developed to treat inflammatory diseases, cancer and sexual dysfunction, announced today it has signed a distribution agreement with Cipher Pharmaceuticals Inc. to distribute Can-Fite's lead drug candidate, CF101, for the treatment of moderate to severe psoriasis and rheumatoid arthritis in the Canadian market upon receipt of regulatory approvals.

23 Mar 2015

Saccharin could potentially lead to development of drugs for difficult-to-treat cancers

Saccharin, the artificial sweetener that is the main ingredient in Sweet 'N Low, Sweet Twin and Necta, could do far more than just keep our waistlines trim. According to new research, this popular sugar substitute could potentially lead to the development of drugs capable of combating aggressive, difficult-to-treat cancers with fewer side effects.

23 Mar 2015

Medical News

TGAC plans to use miniaturised sequencing device to conduct live environmental surveillance

Radiation treatment can be delayed after prostatectomy to prevent side effects, say studies

Mast plans to develop vepoloxamer for chronic heart failure treatment

Glyxambi for Type 2 diabetes treatment now available by prescription across the U.S.

Cipher to distribute Can-Fite’s CF101 for plaque psoriasis and rheumatoid arthritis treatment in Canada

Students at Penn State College of Medicine celebrate matching with residency programs

NNI publishes report on nanotechnology environmental, health, and safety risk science status

EHT expert paper raises important and unanswered questions about safety of wearable tech

Point-Person Project may be more successful with a national infrastructure for clinical trials

MEI Pharma reports top-line results from Pracinostat Phase II study in patients with high-risk MDS

OrthoSensor raises $19 million in Series C Preferred Stock financing

Isis Pharmaceuticals announces positive results from ISIS-ANGPTL3Rx Phase 1 study

Study: Medical practices need support and guidance to adopt new payment models

Everyday Health announces acquisition of Cambridge BioMarketing Group

Low-calorie rice could help potentially reduce obesity rates

Can-Fite, Cipher Pharmaceuticals sign agreement to distribute CF101 in Canada

Saccharin could potentially lead to development of drugs for difficult-to-treat cancers

Acne patients not getting medications prescribed by their dermatologists

Increased sexual activities may be triggered by media use among boys, but not among girls

GenVec collaborates with TheraBiologics to develop NSC-mediated cancer therapeutics

How real-time off-gas analysis improves fermentation process control

Advancing Drug Safety Assessment With AI, Predictive Modeling, and Human-Relevant Data

AI-powered analytics and experimental validation

Latest News